Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study.

Autor: Bassols J; Maternal-Fetal Metabolic Group, [Girona Biomedical Research Institute] IDIBGI, Salt, Spain., Martínez-Calcerrada JM; Maternal-Fetal Metabolic Group, [Girona Biomedical Research Institute] IDIBGI, Salt, Spain., Osiniri I; Clinical Laboratory, Salut Empordà Foundation, Figueres, Spain., Díaz-Roldán F; Pediatrics, Dr. Trueta University Hospital, Girona, Spain., Xargay-Torrent S; Pediatric Endocrinology Group, [Girona Biomedical Research Institute] IDIBGI, Salt, Spain., Mas-Parés B; Maternal-Fetal Metabolic Group, [Girona Biomedical Research Institute] IDIBGI, Salt, Spain., Dorado-Ceballos E; Pediatrics, Dr. Trueta University Hospital, Girona, Spain., Prats-Puig A; Department of Physical Therapy, EUSES University School, University of Girona, Girona, Spain., Carreras-Badosa G; Pediatric Endocrinology Group, [Girona Biomedical Research Institute] IDIBGI, Salt, Spain., de Zegher F; Department of Development & Regeneration, University of Leuven, Leuven, Belgium., Ibáñez L; Endocrinology, Pediatric Research Institute, Sant Joan de Déu Children's Hospital, Barcelona, Spain.; [Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders] CIBERDEM, ISCIII, Madrid, Spain., López-Bermejo A; Pediatrics, Dr. Trueta University Hospital, Girona, Spain.; Pediatric Endocrinology Group, [Girona Biomedical Research Institute] IDIBGI, Salt, Spain.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2019 Dec 10; Vol. 14 (12), pp. e0226303. Date of Electronic Publication: 2019 Dec 10 (Print Publication: 2019).
DOI: 10.1371/journal.pone.0226303
Abstrakt: Background: Metformin treatment (1000-2000 mg/day) over 6 months in pubertal children and/or adolescents with obesity and hyperinsulinism is associated with a reduction in body mass index (BMI) and the insulin resistance index (HOMA-IR). We aimed to ascertain if long-term treatment (24 months) with lower doses of metformin (850 mg/day) normalizes the endocrine-metabolic abnormalities, improves body composition, and reduces the carotid intima-media thickness (cIMT) in pre-puberal and early pubertal children with obesity.
Methods: A pilot double-blind, placebo-controlled trial was conducted on 18 pre-puberal and early pubertal (Tanner stage I-II) children with obesity and risk markers for metabolic syndrome. Patients were randomly assigned (1:1) to receive metformin (850 mg/day) or placebo for 24 months. Clinical, biochemical (insulin, lipids, leptin, and high-sensitivity C-reactive protein [hsCRP]), and imaging (body composition [dual-energy X-ray absorptiometry and magnetic resonance imaging]) parameters as well as cIMT (ultrasonography) were assessed at baseline and at 6, 12, and 24 months.
Results: The 12-month treatment tend to cause a reduction in weight standard deviation scores (SDS), BMI-SDS, leptin, leptin-to-high-molecular-weight (HMW) adiponectin ratio, hsCRP, cIMT, fat mass, and liver fat in metformin-treated children compared with placebo. The effect of metformin on the reduction of BMI-SDS, leptin, leptin-to-HMW adiponectin ratio, hsCRP, and liver fat seemed to be maintained after completing the 24 months of treatment. No changes in insulin sensitivity (HOMA-IR) or adverse effects were detected.
Conclusion: In this pilot study, metformin treatment in pre-puberal and early pubertal children with obesity seemed to improve body composition and inflammation markers. Our data encourage the development of future fully powered trials using 850 mg/day metformin in young children, highlighting its excellent tolerance and potential long-term benefits.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje